Antibodies

14 March 2025

China’s First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease

14 March 2025

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

13 March 2025

Uplizna® (inebilizumab-cdon) significantly improves generalized myasthenia gravis symptoms in acetylcholine receptor autoantibody-positive patients over 52 weeks

13 March 2025

Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive Cancers

13 March 2025

SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113

13 March 2025

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

13 March 2025

BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors

13 March 2025

STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States

12 March 2025

ViiV Healthcare’s investigational broadly neutralising antibody – N6LS – successfully maintains viral suppression in long-acting treatment of HIV

12 March 2025

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

12 March 2025

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

12 March 2025

Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

12 March 2025

Seismic Therapeutic Doses First Cohort in Phase 1 Clinical Trial of S‑1117, a Novel Pan‑IgG Protease Therapy for Antibody-Mediated Diseases

11 March 2025

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

10 March 2025

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

10 March 2025

Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC

10 March 2025

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

10 March 2025

Sun Pharma to Acquire Checkpoint Therapeutics

10 March 2025

U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®

9 March 2025

Innovation fuels the biologics market growth of therapeutic antibodies and proteins in 2024

9 March 2025

Amgen and Kyowa Kirin provide top-line results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis

9 March 2025

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

9 March 2025

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

8 March 2025

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

8 March 2025

Bristol Myers Squibb Receives European Commission Approval for Opdivo®(nivolumab) plus Yervoy®(ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

8 March 2025

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis

7 March 2025

Imfinzi-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

7 March 2025

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

7 March 2025

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

4 March 2025

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

TL1A Inhibitor Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

TSLP Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Report Package: Bispecific Antibodies

Claudin 6: A target opportunity to develop effector-enhanced drug modalities